Ownership and insider activity for Oramed Pharmaceuticals Inc. (ORMP): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes.
Price
| Price | $4.62 |
| Market Cap | $189M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-07-02 | Hexter Joshua | M-Exempt | 50,000 | $184K |
| 2026-07-01 | Hexter Joshua | S-Sale | 137,000 | $611K |
| 2026-07-02 | Hexter Joshua | M-Exempt | 50,000 | $184K |
| 2026-07-01 | Gabay Avraham | S-Sale | 73,360 | $331K |
| 2026-03-30 | KIDRON NADAV | F-InKind | 44,818 | $148K |
| 2026-03-30 | Kidron Miriam | F-InKind | 435,084 | $1.4M |
| 2026-03-17 | Kidron Miriam | A-Award | 119,558 | |
| 2026-03-17 | KIDRON NADAV | A-Award | 167,005 | |
| 2026-03-17 | Hexter Joshua | A-Award | 95,889 | |
| 2026-03-17 | Gabay Avraham | A-Award | 95,889 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.9M | $4.0M | $5.0M | $3.3M | $19.3M | $77.2M | $40.5M | $9.1M | $54.4M | $45.9M |
| Short-term Investments | $27.1M | $16.2M | $25.5M | $29.0M | $20.6M | $16.9M | $115.3M | $153.0M | $87.5M | $79.9M |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $4.6M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $31.2M | $20.3M | $31.0M | $33.3M | $40.5M | $95.3M | $157.1M | $162.6M | $143.2M | $133.3M |
| Property, Plant & Equipment | $16000 | $18000 | $17000 | $24000 | $176000 | $932000 | $1.8M | $1.6M | $1.1M | $1.3M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $42.8M | $38.7M | $47.4M | $34.7M | $44.6M | $128.0M | $161.6M | $220.6M | $155.3M | $230.9M |
| Accounts Payable | $1.4M | $571000 | $1.1M | $1.3M | $594000 | $2.6M | $2.2M | $551000 | $789000 | $443000 |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $51.0M | 0 | $285000 |
| Total Current Liabilities | $3.6M | $5.2M | $4.6M | $5.3M | $4.5M | $6.7M | $5.7M | $53.2M | $5.7M | $19.1M |
| Long-term Debt | $14000 | $18000 | -$7.8M | -$5.6M | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $16.6M | $19.5M | $16.3M | $15.3M | $11.8M | $11.5M | $10.5M | $57.7M | $9.9M | $31.1M |
| Retained Earnings | -$46.0M | -$56.5M | -$69.2M | -$81.1M | -$92.6M | -$114.9M | -$163.1M | -$157.6M | -$176.6M | -$123.4M |
| Total Equity | $26.2M | $19.2M | $31.1M | $19.4M | $32.9M | $115.8M | $151.8M | $163.8M | $146.3M | $199.7M |
| Total Debt | 0 | 0 | 0 | 0 | $75000 | $533000 | $894000 | $51.6M | $372000 | $825000 |
| Net Debt | -$31.0M | -$20.1M | -$30.5M | -$32.3M | -$39.8M | -$93.6M | -$154.8M | -$110.4M | -$141.6M | -$125.1M |
| Working Capital | $27.6M | $15.1M | $26.5M | $28.0M | $36.0M | $88.7M | $151.4M | $109.4M | $137.5M | $114.2M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 4.98 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 1.91 |
Profitability
| Return on Equity | 72.96% |
| Return on Invested Capital | -3.21% |
| Return on Assets | 47.31% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CLNN · CNTB · CNTX · COYA · IFRX · IMA · KLRS
Explore sector: Healthcare · Biotechnology
More sections of ORMP: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks